753.41
price up icon3.25%   23.68
pre-market  プレマーケット:  751.00   -2.41   -0.32%
loading
前日終値:
$729.73
開ける:
$735.785
24時間の取引高:
4.92M
Relative Volume:
1.53
時価総額:
$693.54B
収益:
$40.86B
当期純損益:
$8.37B
株価収益率:
139.02
EPS:
5.4193
ネットキャッシュフロー:
$-2.28B
1週間 パフォーマンス:
-7.19%
1か月 パフォーマンス:
-17.93%
6か月 パフォーマンス:
-3.80%
1年 パフォーマンス:
+26.07%
1日の値動き範囲:
Value
$735.46
$757.37
1週間の範囲:
Value
$711.40
$809.19
52週間の値動き範囲:
Value
$561.65
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
名前
Lilly Eli Co
Name
セクター
Healthcare (1193)
Name
電話
(317) 276-2000
Name
住所
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
職員
43,000
Name
Twitter
@LillyPad
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
LLY's Discussions on Twitter

LLY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
LLY 753.41 693.54B 40.86B 8.37B -2.28B 5.4193
NVO 105.27 465.74B 39.36B 13.79B 9.83B 2.4077
JNJ 153.11 353.35B 87.70B 14.68B 19.03B 13.47
ABBV 167.76 294.70B 55.53B 5.12B 15.62B 3.65
MRK 97.44 248.54B 63.17B 12.15B 14.84B 1.80

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-15 開始されました Wolfe Research Outperform
2024-10-17 開始されました Bernstein Outperform
2024-09-13 再開されました Citigroup Buy
2024-08-12 アップグレード Deutsche Bank Hold → Buy
2024-02-21 ダウングレード DZ Bank Buy → Hold
2024-02-16 繰り返されました Morgan Stanley Overweight
2023-12-21 ダウングレード Daiwa Securities Buy → Outperform
2023-11-09 開始されました Deutsche Bank Hold
2023-10-20 再開されました UBS Buy
2023-08-09 アップグレード Jefferies Hold → Buy
2023-07-26 繰り返されました Citigroup Buy
2023-07-14 開始されました HSBC Securities Buy
2023-05-24 繰り返されました BofA Securities Buy
2023-05-24 繰り返されました UBS Buy
2023-03-13 アップグレード Wells Fargo Equal Weight → Overweight
2023-03-06 開始されました Jefferies Hold
2023-02-15 ダウングレード Societe Generale Hold → Sell
2022-11-18 開始されました Credit Suisse Outperform
2022-09-22 アップグレード UBS Neutral → Buy
2022-05-23 開始されました SVB Leerink Outperform
2022-04-06 再開されました Morgan Stanley Overweight
2022-03-10 開始されました Daiwa Securities Outperform
2022-01-21 アップグレード DZ Bank Hold → Buy
2022-01-03 繰り返されました Bernstein Mkt Perform
2021-12-17 開始されました Goldman Neutral
2021-12-16 繰り返されました BMO Capital Markets Outperform
2021-12-16 繰り返されました BofA Securities Buy
2021-12-09 再開されました Wells Fargo Equal Weight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-10-11 アップグレード Berenberg Hold → Buy
2021-09-29 アップグレード Citigroup Neutral → Buy
2021-08-05 アップグレード DZ Bank Hold → Buy
2021-07-27 再開されました Truist Buy
2021-06-24 繰り返されました Cantor Fitzgerald Overweight
2021-01-19 アップグレード Mizuho Neutral → Buy
2020-12-10 アップグレード Wolfe Research Peer Perform → Outperform
2020-11-10 再開されました Bernstein Mkt Perform
2020-09-29 開始されました Berenberg Hold
2020-09-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-06-16 アップグレード Guggenheim Neutral → Buy
2020-04-21 ダウングレード UBS Buy → Neutral
2020-04-09 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-02-06 開始されました Mizuho Neutral
2019-12-18 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-10-17 再開されました BofA/Merrill Buy
2019-05-28 開始されました Goldman Buy
2019-04-24 アップグレード Edward Jones Hold → Buy
2019-04-11 ダウングレード Guggenheim Buy → Neutral
2019-03-12 開始されました JP Morgan Overweight
2019-01-23 開始されました UBS Buy
2018-11-26 ダウングレード Citigroup Buy → Neutral
2018-10-31 アップグレード Credit Suisse Underperform → Neutral
2018-10-09 開始されました Guggenheim Buy
2018-10-01 繰り返されました SunTrust Buy
2018-09-26 再開されました JP Morgan Overweight
すべてを表示

Lilly Eli Co (LLY) 最新ニュース

pulisher
05:15 AM

Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance

05:15 AM
pulisher
Nov 20, 2024

Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey

Nov 20, 2024
pulisher
Nov 20, 2024

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters

Nov 20, 2024
pulisher
Nov 20, 2024

Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8

Nov 20, 2024
pulisher
Nov 20, 2024

Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

Eli Lilly in pact for novel weight loss therapy (LLY:NYSE) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia

Nov 20, 2024
pulisher
Nov 20, 2024

UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace

Nov 20, 2024
pulisher
Nov 20, 2024

Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online

Nov 20, 2024
pulisher
Nov 20, 2024

Is Novo Nordisk Stock a Buy Right Now? - The Motley Fool

Nov 20, 2024
pulisher
Nov 20, 2024

Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool

Nov 20, 2024
pulisher
Nov 20, 2024

The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance

Nov 20, 2024
pulisher
Nov 20, 2024

Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com

Nov 20, 2024
pulisher
Nov 19, 2024

Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly appoints Jon Moeller to board of directors - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly & Co. stock rises Tuesday, still underperforms market - MarketWatch

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly & Co. (LLY) Announces Board Changes - StreetInsider.com

Nov 19, 2024
pulisher
Nov 19, 2024

Lilly announces changes on board of directors - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers

Nov 19, 2024
pulisher
Nov 19, 2024

Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com

Nov 19, 2024
pulisher
Nov 19, 2024

Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters

Nov 19, 2024
pulisher
Nov 18, 2024

Cramer's Lightning Round: Eli Lilly is a buy - NECN

Nov 18, 2024
pulisher
Nov 18, 2024

Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters

Nov 18, 2024
pulisher
Nov 18, 2024

Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive

Nov 18, 2024
pulisher
Nov 18, 2024

Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa

Nov 18, 2024
pulisher
Nov 18, 2024

Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Benzinga

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette

Nov 18, 2024
pulisher
Nov 18, 2024

Eli Lilly: positive results for tirzepatide - Marketscreener.com

Nov 18, 2024
pulisher
Nov 17, 2024

If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool

Nov 17, 2024
pulisher
Nov 17, 2024

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices

Nov 17, 2024
pulisher
Nov 16, 2024

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company

Nov 16, 2024
pulisher
Nov 15, 2024

Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360

Nov 15, 2024
pulisher
Nov 15, 2024

Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal

Nov 15, 2024
pulisher
Nov 15, 2024

Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024
pulisher
Nov 15, 2024

Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law

Nov 15, 2024

Lilly Eli Co (LLY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general NVO
$105.27
price up icon 2.57%
drug_manufacturers_general JNJ
$153.11
price up icon 0.07%
$167.76
price up icon 0.71%
drug_manufacturers_general MRK
$97.44
price up icon 0.93%
drug_manufacturers_general NVS
$103.09
price down icon 0.17%
大文字化:     |  ボリューム (24 時間):